Cellular Energy
NAD+ is essential to mitochondrial energy metabolism. Whether supplementation improves everyday fatigue depends on the cause of symptoms and has not been established for all patients.
Explore medically supervised NAD+ delivery options with individualized evaluation, realistic expectations, and careful attention to safety and tolerability.
Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme found in every living cell. It participates in reactions that convert nutrients into usable cellular energy and supports enzymes involved in DNA repair, cell signaling, and metabolic regulation.
NAD+ biology is an active area of aging and metabolic research. Oral precursors can raise certain NAD-related biomarkers in humans, but it has not been established that commercial NAD+ therapy reverses aging, prevents cancer or cardiovascular disease, treats depression, or extends human lifespan.
Evidence matters: A biological mechanism is not the same as a proven clinical benefit. Goals, alternatives, uncertainty, product quality, and cost should all be reviewed before treatment.
Patients commonly ask about NAD+-related therapy for energy, mental clarity, recovery, and healthy-aging support. Individual response varies, and evidence for specific wellness outcomes remains limited.
NAD+ is essential to mitochondrial energy metabolism. Whether supplementation improves everyday fatigue depends on the cause of symptoms and has not been established for all patients.
NAD+ pathways are being studied in brain aging and neurologic health, but NAD+ therapy is not an established treatment for memory loss, depression, or neurodegenerative disease.
Research continues in glucose regulation, inflammation, and lipid metabolism. Human trials of NMN have not consistently shown improvements in glucose or lipid measures.
Some precursor studies report changes in selected performance measures, while overall evidence for strength, muscle mass, and recovery remains mixed.
NAD+ levels and metabolism change with age. It remains unknown whether raising NAD+ through commercial therapy meaningfully changes human healthspan or lifespan.
Baseline health, medications, treatment route, tolerance, and goals should guide decisions rather than assuming that a higher NAD+ level always produces a better outcome.
The routes are not interchangeable. Bioavailability, evidence, convenience, cost, and adverse effects differ, and the best option depends on the clinical context.
NAD+ is administered into a vein over a monitored period. IV delivery is widely marketed, but human effectiveness data remain limited. Tolerance is highly rate-dependent, and faster is not better.
Smaller-volume injectable protocols may be offered after medical review. Possible concerns include pain, redness, swelling, bruising, infection, systemic symptoms, and product-quality or sterility risks.
Oral NAD+ products are convenient, but absorption, metabolism, and formulation vary. Evidence that oral intact NAD+ produces the same exposure or effects as IV administration is limited.
These compounds enter NAD+ synthesis pathways through different routes. NR and NMN can increase NAD-related biomarkers in some studies, but optimal dosing, long-term safety, and meaningful clinical benefits remain under investigation.
The body makes NAD+ from vitamin B3 compounds and tryptophan. Food sources include poultry, fish, meat, dairy, legumes, peanuts, seeds, mushrooms, and whole grains. A varied diet supplies niacin and other nutrients needed for normal energy metabolism.
High-dose niacin or nicotinamide can cause adverse effects and may affect liver enzymes, glucose, uric acid, or medication tolerance. NR and NMN products vary in quality, and long-term outcome data are still developing. Supplements should be reviewed alongside kidney or liver disease, pregnancy, cancer treatment, diabetes, gout, and current medications.
NAD+ should not be infused rapidly or pushed through significant discomfort. A slower, individualized rate may improve tolerability.
The infusion should be paused or slowed and the patient reassessed. Chest pain, breathing difficulty, fainting, severe shaking, low blood pressure, persistent vomiting, or signs of an allergic or contamination-related reaction require prompt medical evaluation.
Sterility and sourcing: FDA has reported severe chills, shaking, vomiting, and fatigue after compounded injectable NAD+ products and has warned that food-grade ingredients are not suitable for sterile compounding without appropriate processing. Injectable products should come from a qualified source using ingredients appropriate for sterile drug preparation.
A consultation should clarify what you want to improve and whether a more established evaluation or treatment should come first. Fatigue, brain fog, low mood, and poor exercise tolerance can reflect sleep disorders, anemia, thyroid disease, medication effects, nutritional deficiencies, cardiometabolic conditions, or other causes.
Meet with our medical team to compare available routes, review safety considerations, and decide whether NAD+ therapy or a precursor strategy fits your goals.
Book An Appointment